Marshall University

Marshall Digital Scholar
Biochemistry and Microbiology

Faculty Research

2015

Ascorbic acid and ascorbate-2-phosphate decrease
HIF activity and malignant properties of human
melanoma cells
Sarah Miles
Marshall University, kittlaus1@marshall.edu

Adam P. Fischer
Sandeep J. Joshi
Richard M. Niles
Marshall University, niles@marshall.edu

Follow this and additional works at: http://mds.marshall.edu/sm_bm
Part of the Medical Sciences Commons
Recommended Citation
Miles SL, Fischer AP, Joshi SJ, Niles RM. Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of
human melanoma cells. BMC Cancer. 2015;15(1):867. http://dx.doi.org/10.1186/s12885-015-1878-5

This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Biochemistry and Microbiology by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu, martj@marshall.edu.

Miles et al. BMC Cancer (2015) 15:867
DOI 10.1186/s12885-015-1878-5

RESEARCH ARTICLE

Open Access

Ascorbic acid and ascorbate-2-phosphate
decrease HIF activity and malignant
properties of human melanoma cells
Sarah L. Miles1*, Adam P. Fischer1, Sandeep J. Joshi2 and Richard M. Niles1

Abstract
Background: Hypoxia inducible factor-1 alpha (HIF-1α) is thought to play a role in melanoma carcinogenesis.
Posttranslational regulation of HIF-1α is dependent on Prolyl hydroxylase (PHD 1–3) and Factor Inhibiting HIF (FIH)
hydroxylase enzymes, which require ascorbic acid as a co-factor for optimal function. Depleted intra-tumoral ascorbic
acid may thus play a role in the loss of HIF-1α regulation in melanoma. These studies assess the ability of ascorbic acid
to reduce HIF-1α protein and transcriptional activity in metastatic melanoma and reduce its invasive potential.
Methods: HIF-1α protein was evaluated by western blot, while transcriptional activity was measured by HIF-1
HRE-luciferase reporter gene activity. Melanoma cells were treated with ascorbic acid (AA) and ascorbate 2-phosphate
(A2P) to assess their ability to reduce HIF-1α accumulation and activity. siRNA was used to deplete cellular PHD2 in
order to evaluate this effect on AA’s ability to lower HIF-1α levels. A2P’s effect on invasive activity was measured by the
Matrigel invasion assay. Data was analyzed by One-way ANOVA with Tukey’s multiple comparisons test, or Student-T
test as appropriate, with p < .05 considered significant.
Results: Supplementation with both AA and A2P antagonized normoxic as well as cobalt chloride- and PHD inhibitor
ethyl 3, 4-dihydroxybenzoate induced HIF-1α protein stabilization and transcriptional activity. Knockdown of the PHD2
isoform with siRNA did not impede the ability of AA to reduce normoxic HIF-1α protein. Additionally, reducing HIF-1α
levels with A2P resulted in a significant reduction in the ability of the melanoma cells to invade through Matrigel.
Conclusion: These studies suggest a positive role for AA in regulating HIF-1α in melanoma by demonstrating that
supplementation with either AA, or its oxidation-resistant analog A2P, effectively reduces HIF-1α protein and
transcriptional activity in metastatic melanoma cells. Our data, while supporting the function of AA as a necessary
cofactor for PHD and likely FIH activity, also suggests a potential non-PHD/FIH role for AA in HIF-1α regulation by its
continued ability to reduce HIF-1α in the presence of PHD inhibition. The use of the oxidation-resistant AA analog, A2P,
to reduce the ability of HIF-1α to promote malignant progression in melanoma cells and enhance their response to
therapy warrants further investigation.
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Background
Melanoma, a malignancy derived from pigment producing melanocytes found primarily in the epidermis of the
skin, continues to be the deadliest form of skin cancer.
The global incidence of melanoma is increasing at a faster rate than any other type of cancer. Despite advances
in the treatment of metastatic melanoma it remains an
incurable disease [1]. The only successful cure for melanoma remains early identification of atypical skin
lesions and complete surgical excision before invasion of
the deeper dermal tissue [2, 3]. After dissemination and
metastasis of the primary tumor, limited treatment strategies have encompassed the use of conventional chemotherapy such as dacarbazine [4, 5], with only slightly
more favorable responses with Interleukin-2 (IL-2),
interferon–a2b (IFN-a2b) [3, 6] and more recently, mutant BRAF inhibitors and immunostimulants [1, 7, 8].
However, even after initial positive responses, most melanoma tumors become chemoresistant, ultimately leading to treatment failure and refractory disease.
Many factors play a significant role in the initiation
and progression of melanoma including genetic alterations, and response to the tumor microenvironment
[9–11]. Within the microenvironment, oxygen availability is thought to play a critical role in melanoma carcinogenesis. Hypoxia inducible transcription factor 1
(HIF-1) is a critical mediator of the cellular response to
hypoxia. HIF-1 is a heterodimeric complex of α and β
subunits. While both the HIF-1α and β subunit mRNAs
are constitutively expressed, the HIF-1α subunit protein
is tightly regulated through post-translational hydroxylation by oxygen dependent Fe (II)/2-oxoglutarate (2OG)
prolyl 4-hydroxylase (PHD) enzymes [12, 13]. This hydroxylation targets HIF-1α ubiquitination and degradation
by the proteasome. Under conditions of low oxygen
tension, these hydroxylase enzymes are disabled, allowing
the stabilization and accumulation of HIF-1α in the cell.
Overexpression and stabilization of HIF-1α has been
identified in numerous malignancies [14-17], including
melanoma, and has been implicated in driving its progression and metastatic potential [18-23]. Many tumor
types including melanoma stabilize HIF-1α under nonhypoxic conditions [24, 18, 20, 25]. HIF acts as a positive
regulator of proteins known to be important in melanoma cell invasion, spreading and motility [26]. Given the
relationship between HIF-1α and melanoma progression,
this transcription factor is an attractive target for small
molecule inhibitors [27].
Ascorbic acid (AA) is an essential vitamin in humans
due to the evolutionary loss of the gulonolactone oxidase
(Gulo) enzyme necessary to catalyze the final step in
ascorbic acid synthesis. Its antitumor activity has been
studied extensively over the past decades. Numerous in
vitro and in vivo studies with both human and animal
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tumors demonstrated correlations between tumor AA
levels, reduced HIF-1 activation, and longer disease free
survival [28]. Additionally, low AA levels are associated
with increased HIF-1 activity and more aggressive tumor
phenotypes [29-30]. Furthermore, cancer patients often
have depleted reserves of vitamin C [31-34]. AA has varying effects on cancer initiation, progression and growth.
The aim of this study was to assess the effect of
physiological concentrations of AA on the normoxic
expression and activity of HIF-1α in WM9 metastatic
melanoma cells and to determine the mechanism for its
action. Because of the potential for off target prooxidant effects with the use of high concentrations of
ascorbic acid (mM concentrations), our studies aimed to
determine whether physiologically attainable serum concentrations of AA [35, 36], which would be achievable
through the consumption of vitamin C rich foods (yielding up to 100 μM serum AA) or oral dietary supplements (up to 250 μM serum AA), could effectively
impact HIF-1α in melanoma cells [36]. Under normoxic
culture conditions, addition of AA to culture media at
physiologically relevant concentrations resulted in a
rapid reduction of HIF-1α protein, and HIF activity.
Interestingly, the transcriptional activity of HIF-1 proved
to be more sensitive to AA treatment than the PHD induced degradation of the HIF-1α. We also found that
low physiological concentrations of AA were also able to
antagonize hypoxia-mimetic (cobalt chloride; CoCl2) induced HIF-1α stabilization and increased HIF transcriptional activity. Ascorbate-2-phosphate (A2P), an oxidation
resistant analog of AA, was more potent than its parent
compound in reducing HIF-1α levels.

Materials and methods
Cell culture and reagents

WM1366 and WM9 melanoma cell lines were a generous gift from Dr. Meenhard Herlyn at the Wistar Institute
(University of Pennsylvania). Cells were cultured in RPMI
1640 media supplemented with 10 % fetal bovine serum
(FBS) and 1 % penicillin/streptomycin, in a humidified 5 %
CO2 / 95 % air incubator at 37 °C. L-Ascorbic Acid (AA),
L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate (A2P), Cobalt Chloride (CoCl2), and Ethyl 3, 4dihydroxybenzoate (EDHB) were purchased from Sigma
Chemical Company.
Western Blot Analysis and Antibodies

Nuclear protein extracts were isolated using the NePER
Nuclear and Cytoplasmic Extraction Kit (Pierce), supplemented with Complete Mini Protease Inhibitor Cocktail
(Roche) following the manufacturers protocol. Whole cell
lysates were extracted using whole cell lysis buffer (50 mM
Tris HCl, 150 mM NaCl, 0.25 % SDS, 0.25 % sodium
deoxycholate, 1 mM EDTA; pH 7.4) supplemented with
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Complete Mini Protease Inhibitor Cocktail (Roche). Equal
amounts of protein extracts were separated by SDS-PAGE
on 4-20 % MP-TGX precast polyacrylamide gels (BioRad),
and transferred to nitrocellulose membrane using the
BioRad MINIProtean3 system. Membranes were immunoblotted with antibodies that recognized HIF-1α (1 μl/ml;
R&D Systems), EGLN1 (PHD2; 1:1000; Cell Signaling).
Anti- β-actin (1:10000; 1 h at RT; Sigma) was used to
assess equal protein loading. Immunoblots were visualized
using an enhanced chemiluminescence detection kit (ECL
Prime; GE Healthcare) and imaged on a PhotoDyne
Imaging system (PhotoDyne Technologies). Densitometry
was obtained and quantitated using LabQuant Software.
Small interfering RNA (siRNA) transfection

WM9 cells were transfected at the time of seeding with
10 nM PHD2 siGENOME SMARTpool siRNA (GE
Dharmacon; ThermoScientific) or 10 nM non-targeting
Control siRNA using Lipofectamine RNAimax (Invitrogen)
in standard RPMI culture media following the manufacturers protocol with modifications. Briefly, siRNA transfection complexes were combined in OptiMEM reduced
serum media (Invitrogen) following the RNAimax protocol. Cells were removed from the dish via trypsinization,
and resuspended in standard RPMI media containing the
appropriate siRNA transfection complex. Cells were
immediately seeded into 35 mm tissue culture dishes at
1.0x105 cells per dish. Cells were incubated with transfection reagent overnight. Media was replaced the following
day with complete RPMI +/− CoCl2, EDHB, AA or A2P at
the concentrations and times indicated.
Luciferase reporter assay

2.0X105 cells were seeded in 60 mm culture dishes 24 h
prior to transfection. Cells were incubated overnight
with transfection mixture containing 1.5 μg HIF-1 pTLLuc (5’-3’: GTGACTACGTGCTGCCTAGGTGACTAC
GTGCTGCCTAGGTGACTACGT GCTGCCTAGGTG
ACTACGTGCTGCCTAG; Affymetrix, LR0128) and
0.1 μg pSV-β-galactosidase plasmids (Clontech) and eXtreme Gene 9 transfection reagent (Roche) following the
manufacturers protocol in OptiMEM Reduced Serum
media (Invitrogen). Transfection media was replaced
with standard RPMI the following day, and cells treated
as described. Luciferase activity was measured using the
Luciferase Assay Kit (Promega) and normalized against
β-galactosidase activity that was measured using the βgalactosidase Assay Kit (Promega). Luciferase and β-gal
were measured separately on a SpectraMax M2e 96-well
plate reader.
Matrigel invasion assay

Prior to measuring invasion, WM9 cells were cultured
in 10 cm dishes and maintained for 5 days in standard
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RPMI with or without 100 μM A2P supplementation
under standard culture conditions. Invasion was evaluated
using BD BioCoat Invasion kits (354481; BD Corning).
Cells were dissociated with Accutase (Invitrogen) and
2.5x105 cells were seeded onto the Matrigel coated 6-well
inserts and the assay conducted using the manufacturer’s
protocol with inclusion of 100 μM A2P supplementation
in all media chambers. Plates were incubated 24 h and
cells were then fixed with 100 % methanol for 5 min and
stained with 0.5 % crystal violet for 5 min before being
washed several times in ddH2O to remove excess stain.
Inserts were allowed to dry overnight, then membranes
were removed from the inserts, and placed in a microtube
with 200 μL of 10 % acetic acid for 15 min with vortexing
to elute the dye. Sample absorbance was measured in triplicate at 595 nM on a SpectraMax M2e 96 well plate
reader. A stained membrane without cells was used as the
blank control to account for background staining.

Reverse transcription (RT) and PCR

Total RNA was isolated from untreated WM9 cells using
an RNeasy Mini Kit (Qiagen) following the manufacturers protocol. RNA quality and quantity was assessed
spectrophotometrically using a NanoDrop 2000 UV/Vis
spectrophotometer. cDNA was synthesized from total
RNA using the Advantage RT-for-PCR kit (Clontech
Laboratories, Mount View, CA) following the manufacturers recommended protocol. PCR analysis of target
sequences were generated using the Advantage cDNA kit
(Clontech Laboratories) with the following PCR primers;
EGLN1(PHD2): 5’– GGCAAAGCCCAGTTTGCTGAC3’(forward), 5’ - CCCTCACACCTTTTTCACCTGT-3’
(reverse); EGLN2 (PHD1): 5’- CCAGGCAAGAGAACCA
GGAG-3’(forward), 5’-TCAACGTGCCTTACGTACCC-3’
(reverse); EGLN3 (PHD3): 5’– GGCTTCTGCTACCTG
GACAACT-3’(forward), 5’- AGGATCCCACCATGTAG
CTTG-3’ (reverse). PCR conditions: 95 °C 5 min; 30 cycles of 95 °C 1 min, 57 °C 1 min, 72 °C 1 min; 72°
5 min. PCR products were labeled with Texas Red
(Invitrogen), separated on a 1 % agarose gel and visualized by UV using a PhotoDyne Imaging system (PhotoDyne
Technologies). Target PCR sequences were normalized to
β-actin.

Statistical analysis

Data were analyzed using GraphPad Prism 6 software
(version 6.0f; GraphPad Software, Inc.). Statistical significance was determined by one-way ANOVA followed by
Tukey’s multiple comparisons test, or unpaired Student-t
test as appropriate. Each experiment was performed at
least three times and represented as mean ± SEM. p < 0.05
was considered as a significant difference.
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Results
Ascorbic acid inhibits the normoxic expression of HIF-1α
protein in both invasive and metastatic human melanoma
cell lines

We previously reported [26] that when grown under
normoxic culture conditions, normal human melanocytes and melanoma cell lines isolated from different
stages of the disease had either no detectable HIF-1α
protein (normal melanocytes) or increased amounts of
HIF-1α protein that roughly correlated with their degree
of malignancy. In our initial experiments, we tested the
ability of physiological concentrations of ascorbic acid
(AA) to decrease the amount of HIF-1α protein in a human melanoma cell line (WM1366), isolated from a
vertical growth phase melanoma (Fig. 1a-b). The lowest
concentration of AA (5 μM) dramatically decreased the
normoxic expression of HIF-1α protein in this human
melanoma cell line (Fig. 1B). An increased contrast of the
western blot was used to evaluate the signal of the HIF-1α
protein by densitometry in the AA treated samples (indicated as HIF-1α2 in Fig 1). Using a metastatic human melanoma cell line (WM9), we compared the time and
concentration dependent ability of AA or ascorbate-2phosphate (A2P), an oxidation-resistant analog of AA, to
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decrease the level of HIF-1α protein (Fig 2). At 15 min,
HIF-1α protein is already effectively reduced by approximately 50 % by the 50 μM concentration of AA and A2P.
However, within 30 min, the amount of HIF-1α protein
was decreased by >50 % by all concentration in both the
AA and A2P-treated WM9 cells. The decrease was maintained during the 2 h time period. A2P treatment most effectively reduced HIF-1α protein levels below 15 % by 2 h.
Ascorbic acid and A2P also inhibit hypoxia-mimetic-induced
HIF-1α protein stabilization

It was important to determine whether AA and A2P
could also decrease the much higher levels of HIF-1α
found in hypoxic regions of tumors. We used CoCl2 as a
mimetic of hypoxia since this induced a minimum 15–20
fold increase in WM9 HIF-1α protein level (Fig. 3). Treatment of CoCl2-treated cells with different concentrations
of AA or A2P revealed that the latter compound was also
substantially more effective in reducing the amount
induced HIF-1α protein. Since 100 μM A2P eliminated
essentially all of the HIF-1α protein, compared to 100 μM
AA, which at this concentration had no effect on the protein, we titrated down the amount of A2P and found that
5 μM still reduced CoCl2 induced HIF-1α by 90 % (Fig. 3).

Fig. 1 Effect of ascorbic acid on HIF-1α stabilization in WM1366 radial growth phase melanoma cells. WM1366 cells were treated for 24 h with ascorbic
acid (AA; 5–50 μM) under standard normoxic culture conditions. a Western blot analysis of isolated nuclear extracts reveals considerable reduction in
the amount of stabilized HIF-1α protein following treatment with AA. b Densitometry analysis demonstrates the ability of AA supplementation at
physiologically achievable concentrations to reduce the normoxic overexpression of HIF-1α by approximately 50-60 % in these cells. Protein expression
was normalized to β-actin
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Fig. 2 Effect of ascorbic acid and ascorbate 2-phosphate on HIF-1α stabilization in WM9 metastatic melanoma cells. WM9 metastatic melanoma cells
were treated with increasing concentrations (10, 25 or 50 μM) of ascorbic acid (AA), or the non-oxidizable analog ascorbate 2-phosphate (A2P) for
15–120 min under standard normoxic culture conditions. Western blot analysis of isolated nuclear fractions reveals that both (a) AA and (b) A2P cause
nearly 50 % reduction of normoxic stabilized HIF-1α in these cells as early as 30 min following treatment. Treatment with A2P provided nearly
complete reduction in stabilized HIF-1α by 120 min. Protein expression was normalized to β-actin. All treatments were repeated a minimum of 2
additional times with similar results

Fig. 3 Effect of AA and A2P on cobalt chloride induced HIF-1α protein accumulation in metastatic melanoma. WM9 metastatic melanoma cells
were treated for 24 h with the hypoxia mimetic cobalt chloride (100 μM) in the presence or absence of AA and A2P and nuclear extracts analyzed by
western blot. a The addition of AA (100–500 μM) reveals that 100 μM AA is unable to reduce CoCl2 induced HIF-1α accumulation. Higher concentrations
of AA (250 and 500 μM) are necessary to reduce induced levels of HIF-1α b, while cells treated with A2P (5.0-100 μM) show that A2P efficiently reduces
CoCl2 induced accumulation of HIF-1α at concentrations as low as 5 μM. Protein expression was normalized to β-actin. All treatments were repeated a
minimum of 2 additional times with similar results
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Ascorbic acid and A2P inhibit HIF transcriptional activity
in metastatic human melanoma

While high levels if HIF-1α imply induction of hypoxiainducible genes, this needs to be verified by measuring
HIF transcriptional activity. Therefore, we used a HIFluciferase reporter plasmid transfected into WM9 metastatic human melanoma cells to examine the influence of
AA and A2P on this activity. The hypoxia-mimetic CoCl2
induced a time dependent increase in HIF activity and this
was antagonized by both 100 μM AA and A2P, with the
latter compound being more effective (Fig. 4a). We also
measured the concentration-dependent ability of AA and
A2P to inhibit CoCl2-induced HIF activity (Fig. 4 b,c,d).
AA at 25 μM inhibited HIF activity by ~70 % with 50–
250 μM causing a further decrease in activity (Fig. 4b). In
contrast, 25 μM A2P eliminated >90 % of the HIF activity
(Fig. 4c). Due to this potent effect, we treated the WM9
cells with 2.5-20 μM A2P. There is a significant decrease
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(>95 %) in HIF activity at a concentration of 10 μM A2P
(Fig. 4d).
PHD and AA/A2P inhibition of HIF activity

AA serves as an essential co-factor for PHD enzyme
activity that results in the targeted degradation of HIF1α. Also AA levels are frequently lower in human tumors
than in the surrounding uninvolved tissue [28]. Therefore
we investigated whether AA and A2P decreased HIF-1α
protein in WM9 metastatic melanoma cells through acting on PHD. First we examined whether AA and A2P
could counteract the effect of the PHD inhibitor ethyl 3,4dihydroxybenzoate (EDHB). Figure 5 illustrates the concentration dependent ability of EDHB to stimulate HIF
reporter gene activity in WM9 cells. The maximum stimulation was achieved at 750 μM and this concentration was
used in all further experiments. EDHB is thought to
inhibit PDH activity through both binding to the AA site

Fig. 4 Effect of AA and A2P on HIF-1α transcriptional activity in metastatic melanoma. WM9 metastatic melanoma cells were transiently transfected
with an HIF-1 HRE-luciferase reporter vector. a Transfected WM9 cells were treated with 100 μM CoCl2 with or without AA (100 μM) or A2P (100 μM)
Cells were collected and HIF-1 transcriptional activity was measured by luciferase assay at 24, 48, and 72 h. Both AA and A2P significantly reduced
HIF-1 transcriptional activity at 24 and 48 h, at 72 h, A2P significantly reduced CoCl2 induced activity while AA began to show reduced efficacy by
72 h. b Dose dependent inhibition of CoCl2 induced HIF-1 reporter activity using 25, 50, 100 and 250 μM AA. AA significantly reduced CoCl2 induced
HIF-1 activity at all concentrations, with 25 μM AA beginning to show reduced efficacy. c Dose dependent inhibition of CoCl2 induced HIF-1 reporter
activity by 25, 50, 100 and 250 μM A2P. All concentrations of A2P significantly reduced CoCl2 induced HIF-1 reporter gene activity. For this reason,
lower doses of A2P were then tested. d Low dose titration of A2P dependent inhibition of CoCl2 induced HIF-1 reporter activity using 2.5, 5.0, 10 and
25 μM A2P. A2P demonstrated close to maximum inhibition of HIF-1 activity at concentrations as low as 10 μM, with 5 and 2.5 μM demonstrating little
to no inhibition of activity. All HRE-luciferase activity was normalized to β-galactosidase activity. Data are represented as mean ± SEM of a minimum of
n = 3, analyzed by One-way ANOVA followed by Tukey’s multiple comparisons test; * denotes significant difference from control, p < 0.0001, # denotes
significant difference from CoCl2 treatment alone, p < 0.003-0.0001

Miles et al. BMC Cancer (2015) 15:867

Page 7 of 12

Fig. 5 Effect of ascorbic acid on EDHB induced HIF-1 transcriptional activity in melanoma cells. WM9 metastatic melanoma cells were transiently
transfected with an HIF-1 HRE-luciferase reporter vector. a Transfected cells were treated for 24 h with 0.5, 0.75 and 1.0 mM EDHB. Induction of
HIF-1 transcriptional activity was measured by luciferase assay. EDHB at 0.75 mM was found to be the lowest dose capable of generating
near-maximal induction of HIF-1 transcriptional activity and was thus chosen for subsequent experiments. b Cells were treated for 24 h with
0.75 mM EDHB alone (EDHB), 100 μM AA alone (AA), pretreated with 100 μM AA for 4 h prior to addition of EDHB (AA-EDHB), or treated
with100 μM AA and EDHB concurrently (EDHB/AA). AA effectively reduces EDHB induced HIF-1 transcriptional activity; with AA pretreatment
showing increased efficacy at inhibiting EDHB induced HIF-1 activity vs. concomitant treatment. All HRE-luciferase activity was normalized to
β-galactosidase activity. Data are represented as mean ± SEM of n = 3, analyzed by One-way ANOVA followed by Tukey’s multiple comparisons
test; * denotes significant difference from control, p < 0.0001, # denotes significant difference from EDHB treatment alone, p < 0.0001

on the enzyme and by chelation of iron. Since AA has iron
chelating activity, we tested the ability of AA to reverse
the EDHB stimulation of HIF activity when added prior to
EDHB treatment or when the two compounds were
simultaneously added to the cells. Clearly, AA is more
effective in reversing EDHB stimulation of HIF activity
(through inhibition of PHD activity) when pre-incubated
with the cells (Fig. 5 right panel, AA-EDHB) vs. adding it
at the same time as EDHB (Fig. 5 right panel, EDHB/AA).
Next, we compared the concentration-dependent ability
of A2P vs. AA to reverse the EDHB-stimulated HIF activity (Fig. 6). In contrast to the superior ability of A2P vs.
AA to inhibit cobalt chloride induced HIF-1α levels
(Fig. 4), the potency of A2P and AA to inhibit the EDHBinduction of HIF transcriptional activity was similar.

To more directly determine whether PHD was the target that mediated the ability of AA to decrease HIF-1α
protein levels, we first determined which PHD isoforms
were expressed in the WM9 cells. RT-PCR analysis shows
that PHD2 had the highest RNA expression followed by
PHD1 (Fig. 7b). We could not find any RNA expression of
PHD3. We used PHD2 siRNA to knock-down the
expression of PHD2. The amount of PHD2 protein was
reduced by greater the 90 % in cells treated with the
siPHD2 relative to cells treated with a control siRNA
(Fig. 7a, d). Despite this dramatic decrease in PHD2 protein, AA treatment of the cells still markedly decreased
HIF-1α protein levels. Note that the amount of HIF-1α is
much higher in the siPHD2 vs. control siRNA treated cells
likely due to the absence of PHD2 (Fig. 7a, c).

Fig. 6 Effect of AA and A2P on EDHB induced HIF-1 transcriptional activity in melanoma cells. WM9 metastatic melanoma cells were transiently
transfected with an HIF-1 HRE-luciferase reporter vector. Transfected cells were treated for 24 h with 750 μM EDHB in the presence of a 2.5, 5.0, 10 or
25 μM AA or b 2.5, 5.0, 10 or 25 μM A2P. HIF-1 transcriptional activity was measured by luciferase assay. Data are presented as the mean ± SEM of
n = 3, analyzed by One-way ANOVA followed by Tukey’s multiple comparisons test; * denotes significant difference from control, p < 0.0001, # denotes
significant difference from EDHB treatment alone, p < 0.0001
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Fig. 7 Effect of PHD2 knockdown on reduction of normoxic HIF-1α protein by AA in metastatic melanoma. WM9 metastatic melanoma cells were
transfected using non-targeting control siRNA or siGENOME SMARTpool siRNA against PHD2. a siRNA transfected cells were treated for 24 h with or
without 100 μM AA under standard normoxic culture conditions. HIF-1α and PHD2 were analyzed by western blot, and normalized to β-actin.
Knockdown of PHD2 caused an increase in stabilized HIF-1α protein, however, does not result in loss of effectiveness of AA to reduce accumulated
HIF-1α. b qPCR analysis of PHD1, 2, and 3 isoforms in untreated WM9 metastatic melanoma cells, normalized to β-actin expression. PHD2
appears is the prevalent isoform, however the presences of PHD1 may contribute to the retained activity of AA following PHD2 selective
knockdown. c, d Densitometry analysis of HIF-1α and PHD2 expression following PHD2 knockdown and AA treatment. siRNA experiments
were repeated a minimum of 2 additional times with similar results

A2P inhibits human metastatic melanoma cell invasion in
vitro

Clinical samples of human melanoma express high levels
of HIF-1α [19, 37]. Also, siRNA knockdown of HIF-1α
decreases invasion through Matrigel [25]. Therefore we
tested whether A2P would also decrease the invasion of
WM9 human metastatic melanoma cells. Using the Matrigel in vitro invasion assay (Fig. 8) we found that treatment
of the WM9 cells with A2P decreased invasion by 50 %.

Discussion
Once melanoma progresses to the invasive and metastatic stage, it is very difficult to treat. Therefore, it is
important to identify the molecular changes that contribute to the malignant progression of this disease. Hypoxia
and acquisition of a vascular network together with reprograming of the cancer cell’s metabolism have been noted as
important events required for tumor progression [38, 17].
Accumulation of HIF-1α and HIF-2α was measured via

immunohistochemistry in 46 patient samples of nodular
cutaneous malignant melanomas [19]. Expression of HIF1α and HIF-2α was directly correlated with vascular endothelial growth factor accumulation (VEGF) and also
associated with poor prognosis. A later study of 89 patients with primary cutaneous melanoma did not show
a correlation between
HIF-1α and overall survival or disease-free survival
[20]. However, the relative amount of HIF-1α and more
importantly the activity of HIF as assessed by target gene
expression in the samples was not assayed. HIF-1α was
found under normoxic conditions in malignant melanoma
cells, but not in normal human melanocytes. Further, the
amount of HIF-1α was increased in cells from invasive
and metastatic human melanomas relative to that found
in cells from radial growth phase melanomas. Also knockdown of HIF-1α in the metastatic cells led to marked
decrease in anchorage-independent growth and the ability
to invade through Matrigel [25]. Kuphal et al. [18] verified
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Fig. 8 Effect of A2P treatment on invasive potential of metastatic melanoma cells. WM9 metastatic melanoma cells were maintained in 100 μM
A2P for 5 days under standard normoxic culture conditions. Cells were seeded into Matrigel chambers and assayed for invasion after 24 h.
a Matrigel invasion assay was completed as described in Methods and Materials. Cells grown in the presence of A2P demonstrated a 50 %
reduction in invasion. b Representative photographs of Matrigel invasion chambers. Data are represented as mean ± SEM of n = 3, analyzed by
Student paired T-test; * denotes significant difference from control, p < 0.0087

the constitutive expression of HIF-1α in malignant melanoma and their studies implicate ROS and the NF-κB pathways in contributing to this accumulation of HIF-1α.
Due to their role in tumor progression, HIF-1α and
HIF are targets for the development of new small molecular inhibitors. However, most of the inhibitors to date
work in an indirect fashion such as Bortezomib, a proteasome inhibitor and geldanamycin a Hsp90 inhibitor [39]
In fact, medicinal chemists have deemed that HIF is
undrugable [39].
AA (vitamin C) plays a direct role in regulating both
the activity of PHD and thus the stability of HIF-1α and
the activity of FIH, which inhibits the transcriptional activity of HIF. There are several reports that addition of
AA to cancer cell lines decreases the amount of HIF-1α
protein and also inhibits HIF activity [40–42]. Thus AA
might be useful as a direct inhibitor of the HIF pathway
presumably through its action on the family of Fe (II)-2oxoglutarate-dependent oxygenases, of which PHD and
FIH are members. We investigated this possibility in
human malignant melanoma cells.
In agreement with the study of Knowles, et al. [40] we
found that AA decreased the amount of HIF-1α protein
in malignant melanoma cells grown under either normoxic or hypoxic-mimetic (CoCl2) conditions (Figs. 1, 2
and 3). Further, we showed that A2P, a less oxidizable
analog of AA, was more potent than AA in reducing the
amount of HIF-1α in the melanoma cells treated with
CoCl2 (Figs. 2 and 3). We could not find any other reports on the effect of A2P on HIF-1α levels, but several
studies show that A2P inhibits tumor invasion [43, 44],
while it also inhibits melanogenesis in melanocytes [45].

A2P was also more potent than AA in reducing HIF
reporter gene activity (Fig. 4 panels B & C). Also note that
the ability of AA to inhibit HIF reporter gene activity was
more potent than its ability to decrease HIF-1α protein
levels (compare Fig. 4B with Fig. 3). This finding agrees
with the report of Kuiper et al. [41] that AA preferentially
suppresses the HIF-1 transcriptional response. The authors suggest that this preference is likely due to AA’s ability to stabilize and reduce the iron atom in the PHD and
FIH active sites, with FIH (asparagine hydroxylase) being
more sensitive to fluctuations in intracellular ascorbate.
Next we investigated the hypothesis that the effect of
AA on decreasing HIF-1α in human melanoma cells was
mediated through stimulation of PHD and or FIH activity.
First we used a pharmacological inhibitor of PHD and
likely FIH, ethyl-3, 4-dihydroxybenzoate (EDHB). This inhibitor decreases prolyl hydroxylase activity [46] through
both competition for the AA binding site [47] and inducing an iron deficiency state in cells through a low affinity
for ferric iron [48]. In our melanoma cells, EDBH at or
above a concentration of 750 μM stimulated HIF reporter
gene activity by 4-fold. Since AA pretreatment was more
effective in blocking the EDHB stimulation of HIFreporter gene activity than when EDHB and AA were add
simultaneously to the cells, we suggest that there is competition for either the ferric iron or the AA binding site on
the PHD/FIH enzymes (Fig. 5).
After defining the condition for maximum inhibition
of PHD by EDBH as measured by HIF-reported gene activity, we then measured the concentration-dependent ability
of pre treatment with either AA or A2P to reverse the
inhibition as determined by a decrease in HIF-reporter
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gene activity (Fig 6). In contrast to the hypoxia mimetic
CoCl2 stimulation of HIF-reporter gene activity where A2P
was more potent than AA in reversing this stimulation,
AA and A2P were similar in their potency for reversing
EDHB stimulation of HIF-reporter gene activity. This may
be due to off-target (non-PHD) effects of CoCl2 causing
greater stimulation of HIF-reporter gene activity relative to
the activity induced by the PHD selective inhibitor, EDHB
which may be more sensitive to AA supplementation.
Since chemical inhibitors can have off-target effects,
we used siRNA to knock down the expression of the
PHD2 isoform protein. An RT-PCR survey of the expression of PHD isozymes in the WM9 cells revealed
that these cells express predominantly PHD2 and a small
amount of PHD1, but we could not detect expression of
PHD3. The PHD2 isozyme contributes the majority of
the HIF-hydroxylase activity in cells with normal oxygen
levels [49, 50]. Since PHD1 is localized exclusively in the
nucleus [51], it should only be able hydroxylate HIF-1α
after it has been stabilized and transported into the nucleus. We were able to knockdown the expression of
PHD2 in normoxic WM9 cells by greater than 90 %. As
shown in Fig. 7, this knockdown resulted in a 2.3 fold
higher amount of HIF-1α relative to cells treated with
the control siRNA. Despite the knockdown of PHD2
and the increase in the level of HIF-1α, the addition of
100 μM AA still decreased the amount of HIF-1α by
nearly 90 %. There are at least two explanations for this
unexpected result. One is that AA has additional modes
of action, other than affecting prolyl hydroxylase, which
result in a decrease in the HIF-1α protein. The other
possibility is that in the absence of PHD2, the isozyme
PHD1 can be stimulated by AA and result in the targeting of HIF-1α for degradation by the proteasome.
Regardless of the mechanism for the ability of AA and
A2P to decrease HIF-1α levels and inhibit HIF transcriptional activity, the important question is whether blocking
the HIF pathway decreases some of the malignant properties of the WM9 metastatic melanoma cells. We addressed
this question by measuring the ability of WM9 cells to
invade through Matrigel. A2P was able to inhibit invasion
by 50 %. A2P did not inhibit the proliferation of WM9
cells (data not shown). These findings, together with our
previous work [26] demonstrating that siRNA knockdown
of HIF-1α also inhibits invasion through Matrigel, suggests that AA affects the invasive ability of these metastatic cells through a decrease in HIF-1α/HIF activity.
Although our studies used established human melanoma cell lines, there are some in vivo studies that link
AA levels to tumor aggressiveness. Low AA levels are
associated with increased HIF-1α levels and HIF stimulated gene products in human endometrial tumors [29].
In contrast, increased tumor AA is associated with longer disease-free survival and decreased HIF-1α and HIF
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stimulated gene products in human colorectal tumors.
Specifically in melanoma there is decreased plasma ascorbate levels in stage IV melanoma patients [31] while
an epidemiological study found an association between
dietary vitamin C (AA) and the risk of cutaneous melanoma in a Northern Italian population [52]. IL-2 treatment
of melanoma is unfortunately associated with severe toxicity and it causes a large decrease in circulating levels of
AA. A clinical trial has been proposed to assess the use of
intravenous AA as an adjuvant to IL-2 treatment of melanoma [53]. Thus AA has many potential roles and uses
in human melanoma. The next step will be pre-clinical
investigations of AA/A2P and HIF-1α/HIF activity in animal models that most closely recapitulate the initiation
and progression of human melanoma.

Conclusion
Our studies suggest a positive role for ascorbic acid in
regulating HIF-1α in melanoma. The addition of ascorbic acid can effectively reduce the amount of stabilized
HIF-1α found under normoxic conditions in both vertical growth phase WM1366 and WM9 metastatic melanoma cells. The addition of ascorbic acid also significantly
reduces the transcriptional activity of HIF-1α in WM9
metastatic melanoma cells, resulting in decreased invasive
potential. Our data supports the function of AA as a critical cofactor for PHD, restoring PHD function to reduce
protein accumulation, and likely FIH activity resulting in
significant reduction of HIF-1α transcriptional activity.
However, there may also be non-PHD mediated mechanisms by which AA reduces the level of the HIF-1α protein. The overexpression of intra-tumor HIF-1α, as well as
ascorbic acid deficiency has been noted not only in melanoma, but in other tumor types as well. Further studies to
evaluate the causes of ascorbic acid deficiency and its role
in the loss of HIF-1α regulation in malignancy are needed.
The use of ascorbic acid as a non-toxic adjuvant therapy
to aid in the inhibition of HIF-1α activity in order to
reduce tumor progression and improve patient response
to clinical therapy warrants further investigation.
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